Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.
Immunization with recombinant proteins may provide a safer alternative to live vaccinia virus for prophylaxis of poxvirus infections. Although antibody protects against vaccinia virus infection, the mechanism is not understood and the selection of immunogens is daunting as there are dozens of surface proteins and two infectious forms known as the mature virion (MV) and the enveloped virion (EV). Our previous studies showed that mice immunized with soluble forms of EV membrane proteins A33 and B5 and MV membrane protein L1 or passively immunized with antibodies to these proteins survived an intranasal challenge with vaccinia virus. The present study compared MV protein A27, which has a role in virus attachment to glycosaminoglycans on the cell surface, to L1 with respect to immunogenicity and protection. Although mice developed similar levels of neutralizing antibody after immunizations with A27 or L1, A27-immunized mice exhibited more severe disease upon an intranasal challenge with vaccinia virus. In addition, mice immunized with A27 and A33 were not as well protected as mice receiving L1 and A33. Polyclonal rabbit anti-A27 and anti-L1 IgG had equivalent MV-neutralizing activities when measured by the prevention of infection of human or mouse cells or cells deficient in glycosaminoglycans or by adding antibody prior to or after virus adsorption. Nevertheless, the passive administration of antibody to A27 was poorly protective compared to the antibody to L1. These studies raise questions regarding the basis for antibody protection against poxvirus disease and highlight the importance of animal models for the early evaluation of vaccine candidates.
Fogg
Christiana N
CN
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892-3210, USA.
Americo
Jeffrey L
JL
Earl
Patricia L
PL
Resch
Wolfgang
W
Aldaz-Carroll
Lydia
L
Eisenberg
Roselyn J
RJ
Cohen
Gary H
GH
Moss
Bernard
B
D000281:Administration, Intranasal; D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism; D005260:Female; D006025:Glycosaminoglycans / Q000378:metabolism; D006367:HeLa Cells; D006801:Humans; D007700:Kinetics; D008565:Membrane Proteins; D051379:Mice; D008807:Mice, Inbred BALB C; D011817:Rabbits; D014614:Vaccines, Synthetic / Q000737:chemistry; D014616:Vaccinia virus / Q000378:metabolism*; D014759:Viral Envelope Proteins / Q000378:metabolism; D014760:Viral Fusion Proteins / Q000378:metabolism; D014765:Viral Vaccines / Q000737:chemistry*
C526377:A27 protein, vaccinia virus; D002352:Carrier Proteins; D006025:Glycosaminoglycans; C087715:L1R protein, Vaccinia virus; D008565:Membrane Proteins; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014760:Viral Fusion Proteins; D014765:Viral Vaccines